8-K: Celularity Restructures Debt, Sells & Licenses IP

Celularity Inc. announced a significant balance sheet restructuring, retiring $41.6 million in senior secured debt through the sale and subsequent exclusive licensing of its intellectual property assets.

Summary

• Celularity Inc. completed a major balance sheet restructuring, retiring all $41.6 million in senior secured debt, including principal and accrued interest.
• The company entered into an Asset Purchase Agreement with Celeniv Pte. Ltd. on August 13, 2025, selling certain intellectual property (Patents, Trademarks, Know-How) for a purchase price of $33,812,230.
• The purchase price was used to fully satisfy a $27,000,000 loan from Resorts World Inc. Pte. Ltd. (RWI) and a $6,812,230 promissory note from Tan Sri Dato Lim Kok Thay, both assigned to Celeniv.
• Concurrently, Celularity entered into a License Agreement with Celeniv, granting Celularity an exclusive, irrevocable, worldwide, royalty-bearing, sublicensable license to the sold intellectual property for an initial term of five years.
• Celularity will pay Celeniv a royalty equal to a low double-digit percentage of the Principal Amount Owing ($33,812,230), payable in quarterly installments starting one year from the effective date.
• Celularity holds an exclusive five-year option to repurchase the licensed assets from Celeniv. The repurchase price is a mid eight-digit amount if exercised within one year, or that amount plus a low double-digit percentage of the Principal Amount Owing and any unpaid quarterly payments if exercised later.
• The company also completed an internal restructuring, establishing wholly-owned operating subsidiaries for its four commercial businesses: advanced biomaterial products (Celularity Biomaterials LLC), longevity-focused cell therapy (Celularity Longevity LLC), biobanking (Celularity Biorepository LLC), and contract development and manufacturing (Celularity Advanced Manufacturing LLC).
• Additional subsidiaries include Celularity Discovery & Development, LLC and Celularity Asset Holding LLC.

Sentiment

Score: 8

Explanation: The filing indicates a significant positive financial restructuring by eliminating substantial debt and retaining operational control over key intellectual property. The creation of subsidiaries also suggests a move towards greater operational efficiency and potential for future growth. The main drawbacks are the loss of direct IP ownership and ongoing royalty payments, but these are offset by the immediate debt relief and repurchase option.

Positives

• Elimination of all $41.6 million in senior secured debt, including principal and accrued interest, significantly improving the balance sheet.
• Retained exclusive, irrevocable, worldwide, and sublicensable use of key intellectual property assets through a license agreement.
• Secured an exclusive five-year option to repurchase the intellectual property assets, providing future optionality.
• Expected to gain greater financial flexibility and potential access to lower-cost traditional financing sources.
• Formalized internal structure with new operating subsidiaries to optimize efficiency and financial performance across commercial units.

Negatives

• Celularity no longer directly owns the intellectual property assets, having sold them to Celeniv.
• Required to pay ongoing quarterly royalty payments to Celeniv for the use of the licensed intellectual property.
• Repurchasing the intellectual property in the future will incur a significant cost (mid eight-digit amount, plus potential additional percentages and unpaid royalties).
• The specific royalty percentage and repurchase price (mid eight-digit amount) are redacted, limiting full financial transparency.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from anticipated results.
• Uncertainty regarding the satisfaction of conditions to the closing of the transactions contemplated by the Asset Purchase Agreement and License Agreement.
• Uncertainty regarding the expected occurrence and timing of the closing of the transactions.
• Uncertainty regarding the expected benefits to the Company from the transactions that may or may not be realized within the expected time periods.
• Risk that the company may not be able to exercise its option to repurchase the intellectual property assets within the five-year option period.
• If the repurchase option is not exercised, the license becomes non-exclusive, and royalty rates may change to market rates, potentially impacting profitability.
• Potential for the company or its creditors to take action to effectuate liquidation, dissolution, or winding-up, which could lead to immediate termination of the License Agreement.
• Risks related to the company's ability to maintain and enforce its intellectual property rights, as prosecution and enforcement responsibilities now lie with Celularity, while ownership is with Celeniv.
• The company's ability to obtain all necessary export and import licenses and other consents for the ownership and use of the Purchased IP Assets.
• The company's ability to comply with CFIUS regulations regarding critical technologies, infrastructure, and sensitive personal data.

Future Outlook

The company expects to gain greater financial flexibility and potential access to lower-cost traditional financing sources following the debt restructuring. It also anticipates optimizing efficiency and financial performance across its commercial units through the new internal subsidiary structure.

Management Comments

• "Under the Celeniv agreements announced today, we successfully monetized Celularitys intellectual property assets to retire the Companys senior secured debt in its entirety while retaining exclusive use of the assets for our cell therapy, advanced biomaterials, and biobanking businesses." Robert J. Hariri, M.D., Ph.D., Chairman and CEO.
• "An exclusive five-year right to repurchase those assets from Celeniv gives us additional optionality going forward." Robert J. Hariri, M.D., Ph.D., Chairman and CEO.
• "We believe this agreement results in a major improvement of Celularitys balance sheet with the removal of all the Companys senior secured debt, which was due for repayment in February 2026, as well as the senior secured lenders general security interest in all Company assets." Robert J. Hariri, M.D., Ph.D., Chairman and CEO.
• "We accomplished this while preserving our exclusive use of intellectual property that is operationally aligned with our programs and commercial activities and expect to gain greater financial flexibility and potential access to lower cost traditional financing sources." Robert J. Hariri, M.D., Ph.D., Chairman and CEO.
• "We are deeply grateful to both RWI and Mr. Lim for their continued support of Celularitys mission as we embark on this new chapter." Robert J. Hariri, M.D., Ph.D., Chairman and CEO.
• "This internal restructuring formalizes how we manage Celularity to optimize efficiency and financial performance across the Companys commercial units... as well as our internal discovery and development unit that supports the four commercial units with new product discovery, development, and technology transfer services, and our internal business services unit." Dr. Hariri.
• "We wanted better visibility around the fact that Celularity operates four commercial businesses under one roof, in contrast to the more typical biotechnology enterprises single-shot discovery or development stage programs." Dr. Hariri.

Industry Context

This transaction reflects a strategic move common in the biotechnology and pharmaceutical sectors, where intellectual property is a core asset. Monetizing IP while retaining exclusive usage rights through a license-back arrangement can be a mechanism for companies to raise capital or restructure debt without losing operational control over their core technologies. The creation of distinct operating subsidiaries aligns with a trend towards greater operational clarity and potential for future spin-offs or targeted investments in specific business lines within a diversified biotech company. The focus on regenerative medicine, cell therapy, and biomaterials places Celularity in a high-growth, innovative segment of the healthcare industry.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results to benchmark against. The redacted financial terms (royalty percentage, repurchase price) also limit direct quantitative comparison.

Corporate Governance

Related Party Transactions

• The Asset Purchase Agreement and License Agreement were entered into with Celeniv Pte. Ltd., a company formed by Resorts World Inc. Pte. Ltd. (RWI) and Tan Sri Dato Lim Kok Thay (Mr. Lim).
• RWI was one of Celularity's two senior secured lenders, and Mr. Lim was a former Celularity director and holder of a promissory note from the company.
• The purchase price from Celeniv was used to satisfy loans owed to RWI and Mr. Lim, indicating a transaction with entities closely related to previous lenders and management.

Stakeholder Impact

• Shareholders: Significant improvement to the balance sheet by eliminating substantial debt, potentially reducing financial risk and improving investor confidence. However, the company no longer directly owns its core IP, which could be a long-term concern if the repurchase option is not exercised or is too costly.
• Creditors: The senior secured lenders (RWI and Mr. Lim/Celeniv) had their loans fully satisfied, improving their position. Other creditors may benefit from a stronger balance sheet.
• Employees: The internal restructuring into distinct operating subsidiaries could lead to clearer organizational structures and potentially more focused business units, which might impact roles and responsibilities. No direct impact on employment levels is mentioned.
• Customers/Suppliers: Continued exclusive access to intellectual property ensures business continuity for product development and commercialization, which is positive for customers. No direct impact on suppliers is mentioned.

Next Steps

• Celularity will make quarterly royalty payments to Celeniv, commencing one year from the Effective Date.
• Celularity has the option to purchase the Licensed Technology and Licensed Marks from Celeniv within five years from the Effective Date.
• If the option is not exercised, the parties will negotiate an alternative arrangement for continued use of the licensed technology and marks during a 90-day Negotiation Period.
• If no agreement is reached after the Negotiation Period, the license will become non-exclusive, and royalty rates will change to market rates, with the term extending for another five years for selected IP.
• Celularity will continue to manage its operations through its newly established wholly-owned operating subsidiaries.

Key Dates

Recommendation

While the elimination of $41.6 million in senior secured debt is a significant positive, improving Celularity's balance sheet and financial flexibility, the company has divested its core intellectual property assets. Although it retains exclusive license and a repurchase option, the long-term implications of not owning the IP outright and the ongoing royalty payments introduce new complexities and costs. The redacted financial terms for royalties and repurchase price also limit a full valuation assessment. The internal restructuring is a positive step for operational clarity. Given the mixed implications of debt relief versus IP ownership change, a 'hold' recommendation is appropriate until further clarity on the company's operational performance under the new structure and its long-term IP strategy emerges.

Keywords

Celularity, CELU, SEC Filing, 8-K, Debt Restructuring, Intellectual Property Sale, IP Licensing, Balance Sheet, Biotechnology, Cell Therapy, Regenerative Medicine, Corporate Governance, Asset Purchase Agreement, License Agreement, Debt Retirement, Financial Flexibility, Biomaterials, Biobanking, CDMO